Supporting Health Including Endocrine Treatment for Long Duration
Start Date
8/4/2026
Completion Date
5/1/2027
Summary
This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.
Detailed Description
This research study is a single-arm intervention pilot study to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease prescribed long-term endocrine treatment. The SHIELD portal is designed to help monitor the frequency and variation in cancer and treatment-related issues and to share self-management information and resources to those interested in particular issues or who indicate a specific concern, symptom or side effect on measures designed to assess and track salient symptoms. Research study procedures include screening for eligibility, in-clinic and virtual approaches for recruitment, gaining access and using the SHIELD web- and mobile app-based supportive care portal, and completing of survey assessments on the SHIELD portal. Participation in this research study is expected to last 3 months. It is expected that 30 people will take part in this research study.
Eligibility Criteria
Age Range: 18 years to 49 years
Interventions
SHIELD portal
Conditions
Locations
Dana-Farber Cancer Institute
Boston, Massachusetts 02215
United States